

Daniel E Falk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4192909/publications.pdf>

Version: 2024-02-01

37
papers

2,167
citations

257450

24
h-index

345221

36
g-index

37
all docs

37
docs citations

37
times ranked

1995
citing authors

#	ARTICLE	IF	CITATIONS
1	Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 23-35.	2.4	17
2	Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1431-1443.	2.4	23
3	World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. <i>Addiction</i> , 2020, 115, 1668-1680.	3.3	44
4	Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 158-169.	2.4	60
5	Response to Dr. Mark Litt's Commentary. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 2255-2256.	2.4	0
6	Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. <i>Drug and Alcohol Dependence</i> , 2019, 201, 16-22.	3.2	19
7	Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. <i>Drug and Alcohol Dependence</i> , 2019, 197, 228-235.	3.2	42
8	Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials. <i>JAMA Psychiatry</i> , 2019, 76, 374.	11.0	77
9	Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 979-987.	2.4	41
10	Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies. <i>Handbook of Experimental Pharmacology</i> , 2019, 258, 443-462.	1.8	19
11	Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2453-2465.	2.4	82
12	Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2256-2265.	2.4	43
13	Posttreatment Low-Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders: A 9-Year Follow-Up. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 653-658.	2.4	24
14	Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1054-1062.	2.4	25
15	Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1381-1382.	2.4	5
16	Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. <i>Lancet Psychiatry</i> , 2017, 4, 469-476.	7.4	108
17	Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 179-186.	2.4	123
18	A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. <i>Neuropsychopharmacology</i> , 2017, 42, 1012-1023.	5.4	61

#	ARTICLE	IF	CITATIONS
19	Missing Data in Alcohol Clinical Trials with Binary Outcomes. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1548-1557.	2.4	25
20	Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1368-1379.	2.4	55
21	Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety. <i>Substance Abuse</i> , 2016, 37, 286-298.	2.3	75
22	An exploratory evaluation of Take Control : A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder. <i>Contemporary Clinical Trials</i> , 2016, 50, 178-185.	1.8	13
23	Measures of outcome for stimulant trials: ACTION recommendations and research agenda. <i>Drug and Alcohol Dependence</i> , 2016, 158, 1-7.	3.2	49
24	Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence. <i>Journal of Addiction Medicine</i> , 2015, 9, 296-303.	2.6	50
25	Heterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 579-584.	2.4	233
26	Cumulative Proportion of Responders Analysis (CPRA) as a Tool to Assess Treatment Outcome in Alcohol Clinical Trials. <i>Journal of Studies on Alcohol and Drugs</i> , 2014, 75, 335-346.	1.0	11
27	Alcohol Medications Development: Advantages and Caveats of Government/Academia Collaborating with the Pharmaceutical Industry. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 1196-1199.	2.4	9
28	Methods to Analyze Treatment Effects in the Presence of Missing Data for a Continuous Heavy Drinking Outcome Measure When Participants Drop Out from Treatment in Alcohol Clinical Trials. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 2826-2834.	2.4	48
29	Research Opportunities for Medications to Treat Alcohol Dependence: Addressing Stakeholders' Needs. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 27-32.	2.4	14
30	Five-Year Healthcare Utilization and Costs Among Lower-Risk Drinkers Following Alcohol Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 579-586.	2.4	25
31	Posttreatment Low-Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, E373-80.	2.4	44
32	A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence. <i>Journal of Addiction Medicine</i> , 2013, 7, 277-286.	2.6	220
33	The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders. <i>Neuropsychopharmacology</i> , 2012, 37, 402-411.	5.4	25
34	A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Levetiracetam Extended-Release in Very Heavy Drinking Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 1421-1430.	2.4	41
35	Medications development to treat alcohol dependence: a vision for the next decade. <i>Addiction Biology</i> , 2012, 17, 513-527.	2.6	176
36	A Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of Quetiapine Fumarate XR in Very Heavy Drinking Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 406-416.	2.4	85

#	ARTICLE	IF	CITATIONS
37	Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for AlcoholClinical Trials. Alcoholism: Clinical and Experimental Research, 2010, 34, 2022-2034.	2.4	156